|
See related Rasilez film-coated tab information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Aliskiren |
|
Indications |
Treatment of essential HTN.
Click to view Rasilez detailed prescribing infomation |
|
Dosage |
Initially 150 mg once daily. Dose may be increased to 300 mg once daily.
Click to view Rasilez detailed prescribing infomation |
|
Overdosage |
View Rasilez overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
[Click for Rasilez detailed prescribing infomation] |
|
Special Precautions |
Na &/or vol-depleted patients, renal & hepatic impairment. Diabetic patients. Pregnancy & lactation. Childn <18 yr.
Click to view Rasilez detailed prescribing infomation |
|
Adverse Drug Reactions |
Diarrhoea.
View ADR Monitoring Form |
|
Drug Interactions |
Furosemide, ketoconazole.
View more drug interactions with Rasilez |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Rasilez storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Rasilez mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Rasilez film-coated tablet |
|
Rasilez 150 mg x 28's |
 |
|
Rasilez 300 mg x 28's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Hong Kong: Zuellig
Macau: Four Star |
|
|
|
|
|
